Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
about
Inflammatory breast cancer: clinical progress and the main problems that must be addressedBreast cancer in the personal genomics eraNF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivationUpdate on inflammatory breast cancerMolecular biology of breast cancer metastasis. 'Has it spread?': disarming one of the most terrifying questionsInflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancersFirst description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three casesIn vitro comparative models for canine and human breast cancersA stromal gene signature associated with inflammatory breast cancer.Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cellsMarkers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherinAnalysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients.Array-based DNA methylation profiling for breast cancer subtype discrimination.Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast CancerCharacterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signalingA phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.Cathepsin B: a potential prognostic marker for inflammatory breast cancerConformal microwave array (CMA) applicators for hyperthermia of diffuse chest wall recurrence.Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancerCirculating tumor cells in newly diagnosed inflammatory breast cancer.Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancerMolecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancerNeoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestrationInflammatory breast cancer: is it really a separate entity?BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process.Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screeningDiverse presentations of carcinoma erysipelatoides from a teaching hospital in australiaA comparison of cholesterol uptake and storage in inflammatory and noninflammatory breast cancer cells.Is caveolin-1 a viable therapeutic target to reduce cancer metastasis?Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionRho proteins and cell-matrix interactions in cancer.
P2860
Q21195182-6F81181A-3A85-47F6-A0A4-C132A58F9900Q24602679-63FADC41-3429-48BC-A899-0712DAB16C07Q24653076-0D10B5B6-3551-4BE9-9E4E-5FD74B4133CFQ24797853-4A2242B4-AAE8-432C-88FE-317EC1B15598Q24800902-866AE9FA-6F0E-4B26-A7B5-CB03D1095BD5Q24803667-C3955FFD-4485-449E-8A33-2DD49833BD81Q24805938-4601508F-7798-475C-A40F-B679AB5E3F89Q26752714-428C88D3-3F3D-48EF-B807-F8ACFE4CC274Q30838525-FE5B80BD-7880-49C9-8F3A-7DD842AA1CA2Q31138996-7DB1D0F7-9E55-45C0-8389-02E7519C6372Q33317058-389D8A9F-2611-49DD-8201-5A170921B7CEQ33636065-3C66955E-D00D-43EE-8AE4-2439DCF0F54FQ33689442-BA74DD9A-6223-4D28-B942-7372B39D36B9Q33760216-10E6E6EC-E781-4E72-BA65-781EFDA1C63BQ33796945-C055D2AF-D67E-408F-BA6B-9341476F3C70Q34147662-42B97EEF-F9F5-427D-AC17-411AB6E5E4CDQ34207279-943E4C55-58AD-4DD9-86C2-749D8E048D0CQ34499322-F78C71E6-44C3-4E28-A13E-18BCD4D3A3B3Q34660258-4C064D44-65C7-45F5-857A-05FBB74FBD90Q34743442-B9A8DD4E-0215-4D71-897D-CEFC43D393A2Q34785853-EEDDC4D0-D1EF-49EE-8A7E-BC3EA2AF2467Q35007782-F2EBD213-4DAE-4F33-80DF-F920B077EDF4Q35052773-39C3AACF-D08C-43E7-A933-A16D03F80981Q35217289-9B64F960-B1F7-41CB-B3F8-60831A9ED553Q35448482-001F8328-1C4C-47B5-BC8F-FF48195AD2E8Q35572495-AC234BD9-8445-4CFC-9122-7A1ACCA78475Q35586223-99B22C64-E3B5-4312-9AA2-836629A97F31Q35766493-D018325F-03F0-4313-A560-7CE9DE810B5DQ35829855-9502E975-13CF-44D1-8EFB-4E8BCC258142Q35939285-85EC01CB-0845-4C81-81A4-4FB9CDA30571Q36099273-92526392-299A-4AC6-BBE0-72A3959B9E63Q36243278-7B89FB47-9B14-496E-92A9-4F67DD81A0CEQ36308501-99BFBE33-5AC7-46CD-B258-DDFEE3D8BE79Q36356303-4EF44A74-724F-4A93-A704-6599EFACE049Q36519740-7FB26C79-E620-4B14-B3C5-8EC74C203E29Q36546465-FCBA2221-273F-4460-86EB-A78886E223F4Q36596684-787E0D2B-EC90-4E1C-9CC4-1B8A21AB4521Q36611440-C00407C6-E1D6-494A-BE39-D74AAF1380F1Q36657315-57B40DFF-5158-4F14-A49A-C4596DE3275EQ36857792-E2BB04D5-C0FF-4146-8B1A-4DF49003BA15
P2860
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Molecular biology of breast ca ...... ome and molecular determinants
@nl
Molecular biology of breast ca ...... me and molecular determinants.
@ast
Molecular biology of breast ca ...... me and molecular determinants.
@en
type
label
Molecular biology of breast ca ...... ome and molecular determinants
@nl
Molecular biology of breast ca ...... me and molecular determinants.
@ast
Molecular biology of breast ca ...... me and molecular determinants.
@en
prefLabel
Molecular biology of breast ca ...... ome and molecular determinants
@nl
Molecular biology of breast ca ...... me and molecular determinants.
@ast
Molecular biology of breast ca ...... me and molecular determinants.
@en
P2093
P2860
P921
P3181
P356
P1476
Molecular biology of breast ca ...... me and molecular determinants.
@en
P2093
K L van Golen
S D Merajver
P2860
P2888
P304
P3181
P356
10.1186/BCR89
P407
P577
2000-07-11T00:00:00Z
P5875
P6179
1042268003